Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

They also tend to evolve more rapidly than protein-coding sequences. It is the second ... quarter of this year as market leader Wegovy (semaglutide) from Novo Nordisk showed the first signs ...

The animals produced were genotyped using the following primer sequences: 146a locus 5′forward primer ... the role of miR-146a in SREBP-mediated lipogenesis, we measured SCAP protein levels in ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations.

GLP-1 agonists mimic the natural hormone glucagon-like peptide-1 (GLP-1), produced in ... Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...